Small Cell Lung Cancer Recurrent clinical trials

Explore recruiting small cell lung cancer recurrent clinical trials.

Recruiting small cell lung cancer recurrent studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Small Cell Lung Cancer Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304)

Greece, Austria, Denmark, Czechia, Spain, Romania +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Belgium, Denmark, Italy, Austria, Greece, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib 2024-512581-34-00

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

Italy, Spain, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Small Cell Lung Cancer Recurrent trials by city

Small Cell Lung Cancer Recurrent in Toronto Small Cell Lung Cancer Recurrent in Vancouver Small Cell Lung Cancer Recurrent in Montreal Small Cell Lung Cancer Recurrent in Calgary Small Cell Lung Cancer Recurrent in Edmonton Small Cell Lung Cancer Recurrent in Ottawa Small Cell Lung Cancer Recurrent in Winnipeg Small Cell Lung Cancer Recurrent in Quebec City Small Cell Lung Cancer Recurrent in Hamilton Small Cell Lung Cancer Recurrent in Kitchener Small Cell Lung Cancer Recurrent in London Small Cell Lung Cancer Recurrent in Halifax Small Cell Lung Cancer Recurrent in New York Small Cell Lung Cancer Recurrent in Los Angeles Small Cell Lung Cancer Recurrent in Chicago Small Cell Lung Cancer Recurrent in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease